ClinicalTrials.gg
CompletedNCT00535132Updated May 9, 2014Results posted

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

A Phase 4 interventional study of Oral Risperidone and Paliperidone ER in Schizophrenia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 42 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-09.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
36th of 123
201 · median 100
Started
2007
with 6 others
Phase 4
63 of 127
2 open now
Registered
65th of 127
by date
Lead sponsor
12 of 127
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 127 studies testing risperidone in Schizophrenia, this one is the 36th largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2007, is one of 63 in phase 4, and was the 65th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.

Read the detailed description

Paliperidone ER has been shown to be effective compared to placebo ("a sugar pill") in the acute treatment and maintenance of patients with schizophrenia. Paliperidone ER combines an active metabolite of another antipsychotic, risperidone, with manufacturing technology allowing more gradual release of the drug and less difference in high and low blood levels of the drug. Side effects to medications are sometimes due to wide differences in these high and low blood levels. Recent research has shown that many patients with schizophrenia discontinue their antipsychotic medication due to "subject-choice". Therefore, it is important that research studies attempt to measure patients' satisfaction with antipsychotic medication, in addition to measuring how they respond on tests of effectiveness. This study has been designed to evaluate antipsychotic medication satisfaction in patients who continue to have symptoms of schizophrenia, and who say they are dissatisfied with their current risperidone treatment. The primary outcome is the change in the Medication Satisfaction Questionnaire (MSQ) score, from baseline to the Week 6 endpoint. These patients are randomized (like flipping a coin) as to when their risperidone (4 mg to 6 mg per day) is switched to paliperidone ER. Because the study is 'blinded', neither the study doctor nor the patient will know when treatment with risperidone is stopped and treatment with paliperidone ER begins. Throughout the study all patients continue to receive antipsychotic medication daily. Patients will continue on the same daily dose of risperidone until their randomly assigned switch to paliperidone ER. All patients will be switched to paliperidone ER over the course of study and once switched continue to take paliperidone ER for the remainder of the study. Paliperidone ER is started at 6 mg/day and can be increased to 9 mg/day or 12 mg/day at the doctor's discretion. Effectiveness and safety will be measured at visits scheduled weekly for the first four weeks and then at the Week 6 endpoint. At each visit, patients will be asked to complete psychiatric tests and questionnaires that will measure effectiveness and patient satisfaction with the medicine. They will also complete tests and evaluations for safety, including electrocardiograms (ECGs, electrical tracings of the heart) and blood samples at the beginning and end of the study. Each patient receives two blinded capsules by mouth once daily in the morning for 6 weeks. Patients taking risperidone receive either a 4-mg or 6-mg capsule plus a placebo capsule. When patients are switched, Paliperidone ER is started at 6 mg/day the day after risperidone is discontinued and can be increased to 9 mg/day or 12 mg/day at the doctor's discretion. Paliperidone 3-mg and 6-mg capsules are combined with placebo to equal the total dose in two capsules.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • medication satisfaction, Invega
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be able to understand, in the opinion of the investigator, the form.
  • be diagnosed with schizophrenia
  • report dissatisfaction with current medication
  • have an aspect of schizophrenia management which could potentially benefit from a change in antipsychotic medication
  • receive risperidone 4 mg or 6 mg for at least 4 weeks before the start of the study.

Exclusion criteria

Exclusion Criteria:

  • Unable to swallow study drug whole with the aid of water
  • cannot have received an drug, used an investigational medical device, or participated in a clinical study that altered their medication within 6 months before the first administration of study drug, or have participated in more than 2 investigational drug studies within the past 12 months
  • no other major mental health diagnosis except for tobacco dependance
  • no use of cocaine or heroin within 3 months before the first administration
  • no history of treatment with any antipsychotic in addition to treatment with risperidone, or treatment with paliperidone, within 30 days before the baseline visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    002

    Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks

    Drug: Oral Risperidone

  • Experimental
    001

    Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks

    Drug: Paliperidone ER

Interventions

06

What researchers measure

Primary outcomes

  1. Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint.

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Change from Baseline in MSQ Score at Week 6 Last Observation Carried Forward (LOCF)

Secondary outcomes

  1. Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 2 (Observed).

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Change from Baseline in MSQ Score at Week 2

  2. Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 4 (Observed).

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Change from Baseline in MSQ Score at Week 4

  3. Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 6 (Observed).

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Change from Baseline in MSQ Score at Week 6

  4. Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 2 (Observed).

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Week 2

  5. Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 4 (Observed).

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Week 4

  6. Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 6 (Observed).

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Week 6

  7. Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 6 LOCF.

    The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

    Time frame: Week 6 LOCF

  8. Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score Change From Baseline to the Week 6 Endpoint

    The TSQM is a 14-item subject-assessed evaluation of treatment medication including 4 factors, Effectiveness (items 1-3), Side Effects (items 4-8), Convenience (items 9-11)and Global Satisfaction (items 12-14). Item 14 states "taking all things into account, how satisfied or dissatisfied are you with this medication?" and utilizes the following responses on a 7-point Likert scale: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 0 and best value is 100.

    Time frame: Change from Baseline to Week 6 LOCF

  9. Short Form-36 Health Survey (SF-36) Physical Health Composite Score Change From Baseline to the Week 6 Endpoint

    The SF-36 is a well-validated and widely used quality-of-life instrument employed in numerous disease states, including schizophrenia. It is a self-administered survey that measures eight domains of health including: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role-emotional) and general mental health. Scoring of the SF-36 was based on the SF-36 Manual and Interpretation Guide. Worst value is 0 and best value is 100.

    Time frame: Change from Baseline to Week 6 LOCF

  10. Short Form-36 Health Survey (SF-36) Mental Health Composite Score Change From Baseline to the Week 6 Endpoint

    The SF-36 is a well-validated and widely used quality-of-life instrument employed in numerous disease states, including schizophrenia. It is a self-administered survey that measures eight domains of health including: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role-emotional) and general mental health. Scoring of the SF-36 was based on the SF-36 Manual and Interpretation Guide. Worst value is 0 and best value is 100.

    Time frame: Change from Baseline to Week 6 LOCF

  11. Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to the Week 6 Endpoint

    The PSQI is a 2-part questionnaire that assesses sleep quality and disturbances in seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each domain is rated on a 4-point scale as follows: 0=Not during the past month, 1=Less than once a week, 2=Once or twice a week, 3=Three or more times a week. Total scores range from zero to 21; increasing scores indicate poorer sleep quality and total scores greater than 5 suggest significant sleep disturbance.

    Time frame: Change from Baseline to Week 6 LOCF

  12. Modified COVI Anxiety Scale (m-COVI) Change From Baseline to the Week 6 Endpoint

    The standard COVI Anxiety Scale is an investigator-assessed measure of the severity of anxiety symptoms on 4 items: verbal report, behavior, somatic symptoms, and relationship to study drug. Each dimension is assessed in 5 to 10 minutes using a 5-point scale as follows: 1=Not at all, 2=Somewhat, 3=Moderately, 4=Considerably, to 5=Very much. For this study, the standard COVI Anxiety Scale was modified to improve psychometric properties by incorporating anchor points for symptom severity, frequency, and duration and for functional impairment. Worst value is 20 and best value is 4.

    Time frame: Change from Baseline to Week 6 LOCF

Other outcomes

  1. Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline to Week 6 Endpoint

    The PANSS is a 30-item scale designed to capture numerous symptoms of schizophrenia, including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale as follows: 1=Absent, 2=Minimal, 3=Mild,4=Moderate, 5=Moderate Severe, 6=Severe, 7=Extreme. This scale has been shown to be sensitive to changes associated with medication treatment. In addition to a total score, this assessment yields separate scores along a Positive Syndrome, a Negative Syndrome, and a General Psychopathology Scales. Worst value is 210, best value is 30.

    Time frame: Change from Baseline to Week 6 LOCF

  2. Clinical Global Impression - Severity (CGI-S) Change From Baseline to Week 6 Endpoint

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a subject. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill subjects". Worst value is 7 and best value is 1.

    Time frame: Change from Baseline to Week 6 LOCF

07

Results

Posted Oct 20, 2009

Participant flow

Randomized Population
Participant flow — Randomized Population
MilestonePALI ER Immediate InitiationPALI ER Delayed Initiation
Started100101
Completed100101
Not completed00
Safety Analysis Set
Participant flow — Safety Analysis Set
MilestonePALI ER Immediate InitiationPALI ER Delayed Initiation
Started100101
Completed9899
Not completed22
Withdrew: Did not receive study medication22
Intent-to-Treat (ITT) Analysis Set
Participant flow — Intent-to-Treat (ITT) Analysis Set
MilestonePALI ER Immediate InitiationPALI ER Delayed Initiation
Started9899
Completed9596
Not completed33
Withdrew: No follow-up efficacy data33

Outcome measures

PrimaryMedication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint.

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Change from Baseline in MSQ Score at Week 6 Last Observation Carried Forward (LOCF)
Reported as:
Mean · Points on a scale
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint.
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint.2.5 ± 1.22.3 ± 1.52.4 ± 1.4
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 (p-value based on a paired t-test for a within-group comparison.) · Mean difference (final values): 2.4
SecondaryMedication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 2 (Observed).

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Change from Baseline in MSQ Score at Week 2
Reported as:
Mean · Points on a scale
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 2 (Observed).
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 2 (Observed).2.0 ± 1.41.6 ± 1.41.8 ± 1.4
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): 1.8p-value for within-group comparison based on a paired t-test.
SecondaryMedication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 4 (Observed).

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Change from Baseline in MSQ Score at Week 4
Reported as:
Mean · Points on a scale
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 4 (Observed).
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 4 (Observed).2.4 ± 1.22.1 ± 1.52.3 ± 1.4
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): 2.3
SecondaryMedication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 6 (Observed).

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Change from Baseline in MSQ Score at Week 6
Reported as:
Mean · Points on a scale
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 6 (Observed).
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to Week 6 (Observed).2.5 ± 1.22.4 ± 1.32.5 ± 1.3
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): 2.5p-value for within-group comparison based on a paired t-test.
SecondaryMedication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 2 (Observed).

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Week 2
Reported as:
Number · Participants
Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 2 (Observed).
ParticipantsPALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Satisfied (score 5-7)6343106
Dissatisfied (score 1-4)305282
Statistical analysis
  • Overall · Fisher Exact · p = 0.002P-values for the study group comparisons using dichotomized categories are based on Fisher's Exact Test.
SecondaryMedication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 4 (Observed).

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Week 4
Reported as:
Number · Participants
Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 4 (Observed).
ParticipantsPALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Satisfied (score 5-7)7564139
Dissatisfied (score 1-4)142741
Statistical analysis
  • Overall · Fisher Exact · p = 0.033P-values for the study group comparisons using dichotomized categories are based on Fisher's Exact Test.
Other pre-specifiedPositive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline to Week 6 Endpoint

The PANSS is a 30-item scale designed to capture numerous symptoms of schizophrenia, including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale as follows: 1=Absent, 2=Minimal, 3=Mild,4=Moderate, 5=Moderate Severe, 6=Severe, 7=Extreme. This scale has been shown to be sensitive to changes associated with medication treatment. In addition to a total score, this assessment yields separate scores along a Positive Syndrome, a Negative Syndrome, and a General Psychopathology Scales. Worst value is 210, best value is 30.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Points on a scale
Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline to Week 6 Endpoint
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline to Week 6 Endpoint-13.5 ± 12.2-12.3 ± 14.0-12.9 ± 13.1
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): -12.9p-value for within-group comparison based on a paired t-test.
Other pre-specifiedClinical Global Impression - Severity (CGI-S) Change From Baseline to Week 6 Endpoint

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a subject. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill subjects". Worst value is 7 and best value is 1.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Points on a scale
Clinical Global Impression - Severity (CGI-S) Change From Baseline to Week 6 Endpoint
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Clinical Global Impression - Severity (CGI-S) Change From Baseline to Week 6 Endpoint-0.8 ± 0.9-0.8 ± 1.0-0.8 ± 0.9
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): -0.8p-value for within-group comparison based on a paired t-test.
SecondaryMedication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 6 (Observed).

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Week 6
Reported as:
Number · Participants
Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 6 (Observed).
ParticipantsPALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Satisfied (score 5-7)7771148
Dissatisfied (score 1-4)81624
Statistical analysis
  • Overall · Fisher Exact · p = 0.123 (P-values for the study group comparisons using dichotomized categories are based on Fisher's Exact Test.)
SecondaryMedication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 6 LOCF.

The MSQ is a 7-point, verbally administered, Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 1 (Extremely Dissatisfied) and best value is 7 (Extremely Satisfied).

Time frame:
Week 6 LOCF
Reported as:
Number · Participants
Medication Satisfaction Questionnaire (MSQ) - Categorical Summary - Dichotomized Categories - Week 6 LOCF.
ParticipantsPALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Satisfied (score 5-7)8375158
Dissatisfied (score 1-4)122133
Statistical analysis
  • Overall · Fisher Exact · p = 0.125P-values for the study group comparisons using dichotomized categories are based on Fisher's Exact Test.
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score Change From Baseline to the Week 6 Endpoint

The TSQM is a 14-item subject-assessed evaluation of treatment medication including 4 factors, Effectiveness (items 1-3), Side Effects (items 4-8), Convenience (items 9-11)and Global Satisfaction (items 12-14). Item 14 states "taking all things into account, how satisfied or dissatisfied are you with this medication?" and utilizes the following responses on a 7-point Likert scale: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 0 and best value is 100.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Points on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score Change From Baseline to the Week 6 Endpoint
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score Change From Baseline to the Week 6 Endpoint30.2 ± 22.626.4 ± 23.628.3 ± 23.1
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 (p-value for within-group comparison based on a paired t-test.) · Mean difference (final values): 28.3
SecondaryShort Form-36 Health Survey (SF-36) Physical Health Composite Score Change From Baseline to the Week 6 Endpoint

The SF-36 is a well-validated and widely used quality-of-life instrument employed in numerous disease states, including schizophrenia. It is a self-administered survey that measures eight domains of health including: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role-emotional) and general mental health. Scoring of the SF-36 was based on the SF-36 Manual and Interpretation Guide. Worst value is 0 and best value is 100.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Scores on a scale
Short Form-36 Health Survey (SF-36) Physical Health Composite Score Change From Baseline to the Week 6 Endpoint
Scores on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Short Form-36 Health Survey (SF-36) Physical Health Composite Score Change From Baseline to the Week 6 Endpoint0.8 ± 8.42.1 ± 6.41.5 ± 7.5
Statistical analysis
  • Overall · t-test, 2 sided · p = 0.009 · Mean difference (final values): 1.5p-value for within-group comparison based on a paired t-test.
SecondaryShort Form-36 Health Survey (SF-36) Mental Health Composite Score Change From Baseline to the Week 6 Endpoint

The SF-36 is a well-validated and widely used quality-of-life instrument employed in numerous disease states, including schizophrenia. It is a self-administered survey that measures eight domains of health including: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role-emotional) and general mental health. Scoring of the SF-36 was based on the SF-36 Manual and Interpretation Guide. Worst value is 0 and best value is 100.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Scores on a scale
Short Form-36 Health Survey (SF-36) Mental Health Composite Score Change From Baseline to the Week 6 Endpoint
Scores on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Short Form-36 Health Survey (SF-36) Mental Health Composite Score Change From Baseline to the Week 6 Endpoint6.7 ± 10.37.2 ± 10.67.0 ± 10.4
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): 7.0p-value for within-group comparison based on a paired t-test.
SecondaryPittsburgh Sleep Quality Index (PSQI) Change From Baseline to the Week 6 Endpoint

The PSQI is a 2-part questionnaire that assesses sleep quality and disturbances in seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each domain is rated on a 4-point scale as follows: 0=Not during the past month, 1=Less than once a week, 2=Once or twice a week, 3=Three or more times a week. Total scores range from zero to 21; increasing scores indicate poorer sleep quality and total scores greater than 5 suggest significant sleep disturbance.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Points on a scale
Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to the Week 6 Endpoint
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to the Week 6 Endpoint-2.3 ± 4.3-2.2 ± 4.4-2.3 ± 4.3
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): -2.3p-value for within-group comparison based on a paired t-test.
SecondaryModified COVI Anxiety Scale (m-COVI) Change From Baseline to the Week 6 Endpoint

The standard COVI Anxiety Scale is an investigator-assessed measure of the severity of anxiety symptoms on 4 items: verbal report, behavior, somatic symptoms, and relationship to study drug. Each dimension is assessed in 5 to 10 minutes using a 5-point scale as follows: 1=Not at all, 2=Somewhat, 3=Moderately, 4=Considerably, to 5=Very much. For this study, the standard COVI Anxiety Scale was modified to improve psychometric properties by incorporating anchor points for symptom severity, frequency, and duration and for functional impairment. Worst value is 20 and best value is 4.

Time frame:
Change from Baseline to Week 6 LOCF
Reported as:
Mean · Points on a scale
Modified COVI Anxiety Scale (m-COVI) Change From Baseline to the Week 6 Endpoint
Points on a scalePALI ER Immediate InitiationPALI ER Delayed InitiationOverall
Modified COVI Anxiety Scale (m-COVI) Change From Baseline to the Week 6 Endpoint-1.4 ± 2.8-1.3 ± 3.2-1.3 ± 3.0
Statistical analysis
  • Overall · t-test, 2 sided · p = <0.001 · Mean difference (final values): -1.3p-value for within-group comparison based on a paired t-test.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PALI ER Immediate Initiation—3/98 (3.1%)49/98 (50%)
PALI ER Delayed Initiation—4/99 (4%)56/99 (56.6%)
Overall—7/197 (3.6%)105/197 (53.3%)
Most frequent serious events
Most frequent serious events
EventPALI ER Immediate InitiationPALI ER Delayed InitiationOverall
SchizophreniaPsychiatric disorders2/984/996/197
Pancreatitis acuteGastrointestinal disorders1/980/991/197
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/980/991/197
Most frequent other events
Showing 10 of 73
Most frequent other events
EventPALI ER Immediate InitiationPALI ER Delayed InitiationOverall
InsomniaPsychiatric disorders9/989/9918/197
ConstipationGastrointestinal disorders6/989/9915/197
HeadacheNervous system disorders8/987/9915/197
SomnolenceNervous system disorders5/988/9913/197
NauseaGastrointestinal disorders3/985/998/197
DizzinessNervous system disorders1/985/996/197
SchizophreniaPsychiatric disorders2/984/996/197
InfluenzaInfections and infestations3/981/994/197
Blood prolactin increasedInvestigations3/982/995/197
Dizziness posturalNervous system disorders3/983/996/197

Baseline characteristics

Age, Continuous
Age, Continuous(years)PALI ER Immediate InitiationPALI ER Delayed InitiationTotal
Mean41.1 ± 12.540.2 ± 11.440.6 ± 11.9
Sex/Gender, Customized
Sex/Gender, Customized(participants)PALI ER Immediate InitiationPALI ER Delayed InitiationTotal
Male5853111
Female404686
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PALI ER Immediate InitiationPALI ER Delayed InitiationTotal
American Indian or Alaska Native202
Asian011
Native Hawaiian or Other Pacific Islander101
Black or African American312657
White6169130
More than one race000
Unknown or Not Reported336
08

Study locations

42 sites
  • Cerritos, California, United States
  • Garden Grove, California, United States
  • Huntington Beach, California, United States
  • Pico Rivera, California, United States
  • San Diego, California, United States
  • Santa Ana, California, United States
  • Torrance, California, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Flowood, Mississippi, United States
  • Clementon, New Jersey, United States
  • Brooklyn, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Austin, Texas, United States
  • Irving, Texas, United States
  • Miami, FL, Argentina
  • Buenos Aires, Argentina
  • Ciudad Autonoma De, Argentina
  • Cordoba Crd, Argentina
  • Mendoza Men, Argentina
  • Mendoza, Argentina
  • Rosario, Argentina
  • Barranquilla N/A, Colombia
  • Bogota, Colombia
  • Bogotá S/N, Colombia
  • Bucaramanga S/N, Colombia
  • Plzen, Czech Republic
  • Praha 10, Czech Republic
  • Praha 5, Czech Republic
  • Praha 6, Czech Republic
  • Sternberk 1, Czech Republic
  • Bojnice, Slovakia
  • Bratislava, Slovakia
  • Michalovce, Slovakia
  • Rimavska Sobota, Slovakia
  • Zilina, Slovakia
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Kiev, Ukraine
  • Lviv, Ukraine
  • Odessa, Ukraine
  • Village Stepanovka Kherson, Ukraine
09

References and documents

Publications

  • Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, Awad AG. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010 May;25(3):155-64. doi: 10.1097/YIC.0b013e3283372977. PubMed 20216424 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2007
First posted
Sep 26, 2007
Start
Oct 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Oct 20, 2009
Last update
May 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00535132
Responsible party
Sponsor
First posted
Sep 26, 2007
Start date
Oct 2007
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Oct 20, 2009
Last update
May 9, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risperidone · Paliperidone

Start the discussion